Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/ CD3ζ recombinant gene

Leukemia and Lymphoma

Volumn 49, Issue 7, 2008, Pages 1368-1373

  Yu, Kang ^a   Hu, Yongxian ^a   Tan, Yinxia ^a   Shen, Zhijian ^a   Jiang, Songfu ^a   Qian, Honglan ^a   Liang, Bin ^a   Shan, Daming ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Anti CD20 antibody; CD28; CD3; Cellular immunotherapy; Lymphoma; scFv

Indexed keywords

CD20 ANTIBODY; CD3ZETA CD20 CD28 ANTIBODY CONJUGATE; MONOCLONAL ANTIBODY; RETROVIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL BASED GENE THERAPY; CHIMERA; CONTROLLED STUDY; CYTOKINE RELEASE; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INTERFERON PRODUCTION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANTIGENS, CD20; ANTIGENS, CD28; ANTIGENS, CD3; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOMA; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 47649130059     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802064958     Document Type: Article

References (25)

1. Maloney, D. G., Grillo-L'opez, A. J., White, C. A., Bodkin, D., Schilder, R. J. Neidhart, J. A. et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood, 90, pp. 2188-2195.
2. Kaminski, M. S., Zasadny, K. R., Francis, I. R., Fenner, M. C., Ross, C. W. Milik, A. W. et al. (1996) Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol, 14, pp. 1974-1981.
3. Press, O. W., Eary, J. E., Appelbaum, F. R., Martin, P. J., Nelp, W. B. Glenn, S. et al. (1995) Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346, pp. 336-340.
4. Knox, S. J., Goris, M. L., Trisler, K., Negrin, R., Davis, T. Liles, T. et al. (1996) Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res, 2, pp. 457-470.
5. Schirrmann, T. and Pecher, G. (2005) Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res, 29, pp. 301-306.
6. Moritz, D., Wels, W., Mattern, J. and Groner, B. (1994) Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA, 91, pp. 4318-4322.
7. Hwu, P., Yang, J. C., Cowherd, R., Treisman, J., Shafer, G. E. Eshhar, Z. et al. (1995) In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res, 55, pp. 3369-3373.
8. Weijtens, M. E., Willemsen, R. A., Valerio, D., Stam, K. and Bolhuis, R. L. (1996) Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol, 157, pp. 836-843.
9. Wang, J., Press, O. W., Lindgren, C. G., Greenberg, P., Riddell, S. Qian, X. et al. (2004) Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther, 9, pp. 577-586.
10. Hombach, A., Wieczarkowiecz, A., Marquardt, T., Heuser, C., Usai, L. Pohl, C. et al. (2001) Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol, 167, pp. 6123-6131.
11. Shan, D., Press, O. W., Tsu, T. T., Hayden, M. S. and Ledbetter, J. A. (1999) Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths. J Immunol, 162, pp. 6589-6595.
12. Hu Y-X,Yu, K. (2004) Research advance in malignant tumors and zeta chains of T and NK cells. Foreign medical sciences oncology section, 34, pp. 803-806.
13. Moeller, M., Haynes, N. M., Trapani, J. A., Teng, M. W., Jackson, J. T. Tanner, J. E. et al. (2004) A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther, 11, pp. 371-379.
14. Cooper, L. J., Topp, M. S., Serrano, L. M., Gonzalez, S., Chang, W. C. Naranjo, A. et al. (2003) T-cell clones can be rendered specific for CD19: Toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood, 101, pp. 1637-1644.
15. Jensen, M. C., Cooper, L. J., Wu, A. M., Forman, S. J. and Raubitschek, A. (2003) Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy, 5, pp. 131-138.
16. Hombach, A., Sircar, R., Heuser, C., Tillmann, T., Diehl, V. Kruis, W. et al. (1998) Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signaling chains. Int J Mol Med, 2, pp. 99-103.
17. Patel, S. D., Ge, Y., Moskalenko, M. and McArthur, J. G. (2000) Anti-tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions. J Immunother, 23, pp. 661-668.
18. Maher, J., Brentjens, R. J., Gunset, G., Riviere, I. and Sadelain, M. (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol, 20, pp. 70-75.
19. Losch, F. O., Muller, R., Mutschler, B., Neri, D., Natali, P. G. Reth, M. et al. (2003) Activation of T cells via tumor antigen specific chimeric receptors: The role of the intracellular signaling domain. Int J Cancer, 103, pp. 399-407.
20. Gilham, D. E., O'Neil, A., Hughes, C., Guest, R. D., Kirillova, N. Lehane, M. et al. (2002) Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3 zeta-based chimeric immune receptors. J Immunother, 25, pp. 139-151.
21. Ren-Heidenreich, L., Mordini, R., Hayman, G. T., Siebenlist, R. and LeFever, A. (2002) Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis. Cancer Immunol Immunother, 51, pp. 417-423.
22. Morel, P. A. and Oriss, T. B. (1998) Crossregulation between Th1 and Th2 cells. Crit Rev Immunol, 18, pp. 275-303.
23. Mueller, D. L., Seiffert, S., Fang, W. and Behrens, T. W. (1996) Differential regulation of bcl-2 and bcl-x by CD3, CD28, and the IL-2 receptor in cloned CD4+ helper T cells: A model for the long-term survival of memory cells. J Immunol, 156, pp. 1764-1771.
24. Mor, F. and Cohen, I. R. (1996) IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis: Correlation with induction of Bcl-2. J Immunol, 156, pp. 515-522.
25. Radvanyi, L. G., Shi, Y., Vaziri, H., Sharma, A., Dhala, R. Mills, G. B. et al. (1996) CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol, 156, pp. 1788-1798.